Abstract

Hepatitis C in prison populations is now a major public health problem, and large numbers of correctional facilities have no comprehensive management program, often because of formidable projected costs and tightening budget constraints. The North Dakota Department of Corrections and Rehabilitation has operated a management and therapy program since 2002 using consensus interferon and ribavirin with 45% cost savings. The program has provided excellent sustained viral responses: 54.2% for genotype 1 hepatitis C, 75% for genotypes 2 and 3, and 63.6% overall.

Links

Publisher Full Text

Authors

Martin CK, Hostetter JE, Hagan JJ

Institution

Medcenter One Health Systems, 222 N 7th St, Bismark, ND 58501, USA. kentmartin@bis.midco.net

Source

American journal of public health 100:1 2010 Jan pg 13-7

MeSH

Adolescent
Adult
Antiviral Agents
Female
Health Care Costs
Hepatitis C
Humans
Interferon Type I, Recombinant
Male
Middle Aged
North Dakota
Prisoners
Prisons
Program Evaluation
Ribavirin
Treatment Outcome
Young Adult

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20007626